Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial

C. Collins, J. F. Eary, G. Donaldson, C. Vernon, N. E. Bush, S. Petersdorf, R. B. Livingston, E. E. Gordon, C. R. Chapman, F. R. Appelbaum

Research output: Contribution to journalArticlepeer-review

268 Scopus citations


Samarium-153-ethylenediaminetetramethylene phosphonic acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with bony metastases were treated with doses beginning at 0.5 mCi/kg (18.5 MBq/kg), escalating in 0.5-mCi (18.5 MBq) increments to 3.0 mCi/kg (111 MBq/kg). Pain response after treatment was assessed as well as hematologic and serum chemistry parameters. Pain palliation with a mean duration of 2.6 mo was present in 74% of the patients. Toxicity was exclusively hematologic at the highest dose levels. No infectious or bleeding complications occurred, with 45 of the 52 (86%) patients demonstrating complete hematologic recovery. Patients receiving higher doses had significantly greater reductions in serum prostate specific antigen and serum prostatic acid phosphatase levels. The patients receiving greater doses also showed a trend toward improved survival.

Original languageEnglish (US)
Pages (from-to)1839-1844
Number of pages6
JournalJournal of Nuclear Medicine
Issue number11
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial'. Together they form a unique fingerprint.

Cite this